Antibody–Drug Conjugate Payloads; Study of Auristatin Derivatives
Authors:
- 1 March 2020
- journal article
- review article
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 68 (3) , 201-211
Abstract
Auristatins are important payloads used in antibody drug conjugates (ADCs), and the most well-known compound family member, monomethyl auristatin (MMAE), is used in two Food and Drug Administration (FDA)-approved ADCs, Adcetris® and Polivy®. Multiple other auristatin-based ADCs are currently being evaluated in human clinical trials and further studies on this class of molecule are underway by several academic and industrial research groups. Our group's main focus is to investigate the structure–activity relationships (SAR) of novel auristatins with the goal of applying these to next generation ADCs. Modifications of the auristatin backbone scaffold have been widely reported in the chemical literature focusing on the terminal subunits: P1 (N-terminus) and P5 (C-terminus). Our approach was to modulate the activity and hydrophilic character through modifications of the central subunits P2-P3-P4 and thorough SAR study on the P5 subunit. Novel hydrophilic auristatins were observed to have greater potency in vitro and displayed enhanced in vivo antitumor activity when conjugated via protease-cleavable linkers and delivered intracellularly. Analysis of ADC aggregation also indicated that novel hydrophilic payloads enabled the synthesis of high-drug-to-antibody ratio (DAR) ADCs that were resistant to aggregation. Modification of the central peptide subunits also resulted in auristatins with potent cytotoxic activity in vitro and these azide-modified auristatins contain a handle for linker attachment from the central portion of the auristatin backbone.Keywords
This publication has 62 references indexed in Scilit:
- Design, Synthesis, and Biological Evaluation of Antibody−Drug Conjugates Comprised of Potent Camptothecin AnaloguesBioconjugate Chemistry, 2009
- Selection of Reaction Additives Used in the Preparation of Monomeric Antibody−Calicheamicin ConjugatesBioconjugate Chemistry, 2007
- Phase II study of intravenous TZT‐1027 in patients with advanced or metastatic soft‐tissue sarcomas with prior exposure to anthracycline‐based chemotherapyCancer, 2006
- Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancersInvestigational New Drugs, 2005
- Phase II trial of dolastatin-10 in patients with advanced breast cancerInvestigational New Drugs, 2005
- Antitumor Activity of TZT‐1027, a Novel Doiastatin 10 DerivativeJapanese Journal of Cancer Research, 1997
- Synthesis and Antitumor Activity of Novel Dolastatin 10 Analogs.Chemical and Pharmaceutical Bulletin, 1995
- Cytostatic Effects of Dolastatin 10 and Dolastatin 15 on Human Leukemia Cell LinesLeukemia & Lymphoma, 1992
- Antineoplastic agents. 190. Isolation and structure of the cyclodepsipeptide dolastatin 14The Journal of Organic Chemistry, 1990
- Antineoplastic agents. 3. Structure of the cyclic peptide dolastatin 3 from Dolabella auriculariaJournal of the American Chemical Society, 1982